doxazosin has been researched along with Body Weight in 13 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 12-week double-blind study was performed to compare the safety and efficacy of doxazosin, prazosin and placebo in 172 patients with essential hypertension." | 9.06 | Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. ( Madsbu, HP; Torvik, D, 1986) |
| " After clinical and laboratory evaluation without treatment for at least two weeks, the two groups were treated with enalapril 5-10 or 20 mg daily plus doxazosin at the dosage of 1-2-4- or 8 mg daily; they were observed for 24 weeks." | 6.68 | [Evaluation of the efficacy and tolerance of doxazosin vs. enalapril inaged patients with light to moderate arterial hypertension]. ( Ansuini, R; Curnis, A; Gallucci, M; Malacco, E; Puddu, P; Pupita, F, 1995) |
| "Essential hypertension is characterized by an insulin-resistance state that may be responsible for the increased atherogenesis typical of this disease." | 6.67 | Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension. ( Appendino, M; Giorda, C, 1993) |
| "Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and NGF-beta to the baseline values." | 5.33 | Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. ( Chang, H; Fang, WJ; Liou, JY; Shyu, KG; Wang, BW, 2005) |
| "A 12-week double-blind study was performed to compare the safety and efficacy of doxazosin, prazosin and placebo in 172 patients with essential hypertension." | 5.06 | Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. ( Madsbu, HP; Torvik, D, 1986) |
| " After clinical and laboratory evaluation without treatment for at least two weeks, the two groups were treated with enalapril 5-10 or 20 mg daily plus doxazosin at the dosage of 1-2-4- or 8 mg daily; they were observed for 24 weeks." | 2.68 | [Evaluation of the efficacy and tolerance of doxazosin vs. enalapril inaged patients with light to moderate arterial hypertension]. ( Ansuini, R; Curnis, A; Gallucci, M; Malacco, E; Puddu, P; Pupita, F, 1995) |
| "Essential hypertension is characterized by an insulin-resistance state that may be responsible for the increased atherogenesis typical of this disease." | 2.67 | Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension. ( Appendino, M; Giorda, C, 1993) |
| "Doxazosin treated rats had significantly heavier prostates compared to control rats." | 1.33 | Molecular classification of doxazosin-induced alterations in the rat prostate using gene expression profiling. ( Foster, HE; Latifpour, J; Mane, S; Shin, D; Yono, M, 2005) |
| "Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and NGF-beta to the baseline values." | 1.33 | Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. ( Chang, H; Fang, WJ; Liou, JY; Shyu, KG; Wang, BW, 2005) |
| "Doxazosin treatment prevented the impairment in endothelium-dependent vascular relaxation in the high cholesterol/antioxidant-deficient group." | 1.30 | Effect of doxazosin on endothelial dysfunction in hypercholesterolemic/antioxidant-deficient rats. ( Coffee, K; Guerra, J; Hayakawa, H; Raij, L, 1997) |
| "Doxazosin treatment partially prevented the accumulation of cholesterol and triglycerides in the liver." | 1.28 | Effects of the selective alpha 1-antagonist, doxazosin, on hepatic lipid levels and metabolism in the golden hamster. ( Birkenhäger, JC; Jansen, H, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 8 (61.54) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yono, M | 1 |
| Foster, HE | 1 |
| Shin, D | 1 |
| Mane, S | 1 |
| Latifpour, J | 1 |
| Shyu, KG | 1 |
| Liou, JY | 1 |
| Wang, BW | 1 |
| Fang, WJ | 1 |
| Chang, H | 1 |
| Justulin, LA | 1 |
| Delella, FK | 1 |
| Felisbino, SL | 1 |
| McLeod, SD | 1 |
| Cairncross, KD | 1 |
| Tomiyama, H | 1 |
| Kushiro, T | 1 |
| Abeta, H | 1 |
| Ishii, T | 1 |
| Takahashi, A | 1 |
| Furukawa, L | 1 |
| Asagami, T | 1 |
| Hino, T | 1 |
| Saito, F | 1 |
| Otsuka, Y | 1 |
| Giorda, C | 1 |
| Appendino, M | 1 |
| Dines, CD | 1 |
| Cotter, MA | 1 |
| Cameron, NE | 1 |
| Puddu, P | 1 |
| Gallucci, M | 1 |
| Curnis, A | 1 |
| Pupita, F | 1 |
| Ansuini, R | 1 |
| Malacco, E | 1 |
| Raij, L | 1 |
| Hayakawa, H | 1 |
| Coffee, K | 1 |
| Guerra, J | 1 |
| Jansen, H | 1 |
| Birkenhäger, JC | 1 |
| Jansson, JH | 1 |
| Johansson, B | 1 |
| Boman, K | 1 |
| Nilsson, TK | 1 |
| Ames, RP | 1 |
| Chrysant, SG | 1 |
| Gonzalez, F | 1 |
| Schnaper, HW | 1 |
| Spann, S | 1 |
| Velasquez, MT | 1 |
| Torvik, D | 1 |
| Madsbu, HP | 1 |
5 trials available for doxazosin and Body Weight
| Article | Year |
|---|---|
Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension.
Topics: Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Doxazosin; Female; Follow-Up Studies; Gluco | 1993 |
[Evaluation of the efficacy and tolerance of doxazosin vs. enalapril inaged patients with light to moderate arterial hypertension].
Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Body Weight; D | 1995 |
Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Body Weight; Double-Blind Method; Doxazosi | 1991 |
Effectiveness of doxazosin in systemic hypertension.
Topics: Adult; Antihypertensive Agents; Body Weight; Double-Blind Method; Doxazosin; Drug Administration Sch | 1989 |
Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Body Weight; Clinical Trials as Topic; Double-Blind Method; Do | 1986 |
8 other studies available for doxazosin and Body Weight
| Article | Year |
|---|---|
Molecular classification of doxazosin-induced alterations in the rat prostate using gene expression profiling.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals | 2005 |
Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart.
Topics: Acetylcysteine; Animals; Antihypertensive Agents; Aorta; Arteries; Blotting, Western; Body Weight; C | 2005 |
Doxazosin reduces cell proliferation and increases collagen fibers in rat prostatic lobes.
Topics: Animals; Apoptosis; Body Weight; Cell Proliferation; Collagen; Doxazosin; Epithelial Cells; In Situ | 2008 |
Preliminary evidence of a synergistic alpha 1- and beta 1-adrenoceptor regulation of rat pineal hydroxyindole-O-methyltransferase.
Topics: Acetylserotonin O-Methyltransferase; Aging; Animals; Body Weight; Circadian Rhythm; Doxazosin; Fencl | 1995 |
Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor.
Topics: Analysis of Variance; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Gl | 1994 |
Nerve function in galactosaemic rats: effects of evening primrose oil and doxazosin.
Topics: Animals; Body Weight; Doxazosin; Fatty Acids, Essential; Galactose; gamma-Linolenic Acid; Hypolipide | 1995 |
Effect of doxazosin on endothelial dysfunction in hypercholesterolemic/antioxidant-deficient rats.
Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Body Weight; Doxazosin; Endothelium, Vascular; | 1997 |
Effects of the selective alpha 1-antagonist, doxazosin, on hepatic lipid levels and metabolism in the golden hamster.
Topics: Adrenergic alpha-Antagonists; Animals; Body Weight; Cholesterol; Cricetinae; Doxazosin; Hydroxymethy | 1991 |